Sarfaraz K. Niazi, PhD, examined the new FDA guideline that acts as an invitation to biosimilar developers to decrease the cost of testing, potentially opening the door for companies to reduce nonclinical testing of biosimilars entirely.
I gasped in May 2023 when I read the FDA guidance “Generally Accepted Scientific Knowledge (GASK) in Applications for Drug and Biological Products: Nonclinical Information” that leaves the doors open to reduce nonclinical testing of biosimilars. The guidance describes the 2 circumstances in which sponsors can rely on GASK in their product development programs to meet relevant approval requirements:
For example, in some cases, a drug has either on- or off target impacts on a biological pathway or molecular mechanism of action that is known to result in adverse effects at clinically relevant exposures based on the operation of the biologicalpathway.
Thus,it may be appropriate to rely on GASK regarding the impact of the pathway rather than to conduct specific pharmacology and toxicology studies intended to measure the impact of the pathway. Therapeutic proteins act by receptor binding, which leads to a pharmacodynamic response that brings the pharmacological response that forms the basis of the clinical response.
Unlike chemical drugs, biological drugs' toxicity depends entirely on pharmacology; this established scientific knowledge (GASK) should support claims of the same toxicology profile if the receptor-binding properties are highly similar. This will reduce in situ testing in the analytical assessment of biosimilar candidates. There is no need to include dozens of tests, even in an orthogonal mode, to prove what is already proven. The same conclusion will be drawn in functional testing, leaving the testing to only those process-related attributes such as post-translational modifications, aggregates, impurities, and other readily analyzed attributes.
One limit of the GASK allowance may extend to structure testing since the 3D structure depends entirely on the primary amino acid chain sequence. The 3D structure prediction algorithms AlfphaFold2 and ESMFold will always yield the same 3D if the identical sequence is readily analyzed with the highest confidence.
The FDA guidance is critical since it acknowledges that the developers have been questioning this concession, but the terminology “generally accepted” is very important. How does one establish that a fact is generally established? It is based on “scientific knowledge,” but what constitutes scientific knowledge? Is it a peer-reviewed publication or a general belief in the scientific community? The burden of establishing these 2 elements will lie on the developer.
Still, since the doors are open, I anticipate competent developers taking the most advantage of these newly found concessions to reduce their cost of development and avoid the possibility of redundant testing leading to contradictory findings. This forward-thinking of the FDA teaches us to bring rational approaches to developing biosimilars and not follow the guidelines that had considered them new biologics when biosimilars were introduced.
Biosimilarity should be established based on comparison with the reference product for the product-related attributes and compliance with scientifically justified process-related attributes, an idea that has long been debated; what is a critical quality attribute? Initially, the FDA and all other agencies included just about every process-related attribute as critical attributes, despite realizing that the release specification attributes are process-related and complied with every batch. Essentially, this meant that what the FDA has accepted as good enough for patients may not be good enough for the FDA.
An excellent example to consider is the protein content that is generally allowed a 3% variability, but if this is also declared as a critical attributed and compared with the reference product, the test may fail even if the variation is less than 3%. This was the subject of the first FDA guidance, that was withdrawn to overcome this problem. The GASK also opens the doors for developers to challenge the FDA on what is a critical quality attribute. The GASK application will remove all testing that is part of the release specification from the analytical assessment. However, this may still require testing reference products to establish release specifications.
Overall, it is a tremendous scientific step taken by the FDA. It is now up to the developers to use these concessions best.
Reference
Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873): 583-589. doi: 10.1038/s41586-021-03819-2
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Long-Term Data Support Use of Eculizumab Biosimilar as Soliris Alternative in PNH
January 28th 2025Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in patients with paroxysmal nocturnal hemoglobinuria (PNH), according to a Russian study that expanded on a previous phase 3 study.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Biosimilar Associations and Stakeholders Representing Biosimilars
January 20th 2025Sarfaraz K. Niazi, PhD, dives into the role that biosimilar associations and organizations play in promoting biosimilars as well as how their stakeholder demographic and main objectives differ from one another.
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
January 13th 2025The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.